May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

First Page		Document Content
Date: 2014-05-29 15:30:33 Genetic genealogy BioMarin Pharmaceutical Glycogen storage disease type II Acid alpha-glucosidase Lysosomal storage disease Mucopolysaccharidosis Alglucosidase alfa Neuronal ceroid lipofuscinosis Tetrahydrobiopterin Health Rare diseases Medicine		May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im Add to Reading List Source URL: www.apjohnventures.com Download Document from Source Website File Size: 12,70 KB Share Document on Facebook

	How one patient with a rare disease coped with his genetic disorder DocID: 1r9mW - View Document
	CrossMark_Color_flat+click DocID: 1r0lC - View Document
	What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive DocID: 1lIxr - View Document
	MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme. DocID: 1fJSQ - View Document
	May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im DocID: 1aiEg - View Document